BioCentury
ARTICLE | Clinical News

Bavarian Nordic's ProstVac misses OS endpoint in Phase III for CRPC

May 25, 2018 3:31 PM UTC

Bavarian Nordic A/S (CSE:BAVA) said ProstVac rilimogene galvacirepvec alone and in combination with GM-CSF both missed the primary endpoint of improving overall survival (OS) vs. placebo in the Phase III PROSPECT trial to treat metastatic castration-resistant prostate cancer (CRPC) (34.8 and 33.9 months, respectively, vs. 34.7 months, p=0.4 and p=0.66). The data were released in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago.

The double-blind, international trial enrolled 1,297 men with asymptomatic or minimally symptomatic metastatic CRPC. In September, an IDMC recommended discontinuing PROSPECT for futility based on a preplanned interim analysis (see BioCentury, Sept. 15, 2017)...